Claire J. Cairney

Claire J. Cairney

Auto-generated profile, based on publicly available information

Claire J. Cairney

Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
KLKyle Lafferty-Whyte
Kyle Lafferty-Whyte
CCClaire J. Cairney
Claire J. Cairney
NJNigel B. Jamieson
Nigel B. Jamieson
KOKarin A. Oien
Karin A. Oien
WKW. Nicol Keith
W. Nicol Keith


17 August 2009 in Oncogene
Verified
Journal Article
Open access
PDF file
KLK Lafferty-Whyte
K Lafferty-Whyte
CCC J Cairney
C J Cairney
MWM B Will
M B Will
NSN Serakinci
N Serakinci
MDMaria Grazia Daidone
Maria Grazia Daidone
WKW N Keith
W N Keith
Telomere length is maintained by two known mechanisms, the activation of telomerase or alternative lengthening of telomeres (ALT). The molecular mechanisms regulating the ALT phenotype are poorly understood and it is unknown how the decision of which pathway to activate is made at the cellular level. We have shown earlier that active repression of telomerase gene expression by chromatin remodelling of the promoters is one mechanism of regulation; however, other genes and signalling networks are likely to be required to regulate telomerase and maintain the ALT phenotype. Using gene expression profiling, we have uncovered a signature of 1305 genes to distinguish telomerase-positive and ALT cell lines. By combining this with the gene expression profiles of liposarcoma tissue samples, we refined this signature to 297 genes. A network analysis of known interactions between genes within this signature revealed a regulatory signalling network consistent with a model of human telomerase reverse transcriptase (hTERT) repression in ALT cell lines and liposarcomas. This network expands on our existing knowledge of hTERT regulation and provides a platform to understand differential regulation of hTERT in different tumour types and normal tissues. We also show evidence to suggest a novel mesenchymal stem cell origin for ALT immortalization in cell lines and mesenchymal tissues.

1 September 2015 in Molecular Biology of the Cell
Verified
Journal Article
Open access
PDF file
MSMahito Sadaie
Mahito Sadaie
CDChristian Dillon
Christian Dillon
AYAndrew R. J. Young
Andrew R. J. Young
CCClaire J. Cairney
Claire J. Cairney
LGLauren S. Godwin
Lauren S. Godwin
MNMasashi Narita
Masashi Narita
Cellular senescence is a widespread stress response and is widely considered to be an alternative cancer therapeutic goal. Unlike apoptosis, senescence is composed of a diverse set of subphenotypes, depending on which of its associated effector programs are engaged. Here we establish a simple and sensitive cell-based prosenescence screen with detailed validation assays. We characterize the screen using a focused tool compound kinase inhibitor library. We identify a series of compounds that induce different types of senescence, including a unique phenotype associated with irregularly shaped nuclei and the progressive accumulation of G1 tetraploidy in human diploid fibroblasts. Downstream analyses show that all of the compounds that induce tetraploid senescence inhibit Aurora kinase B (AURKB). AURKB is the catalytic component of the chromosome passenger complex, which is involved in correct chromosome alignment and segregation, the spindle assembly checkpoint, and cytokinesis. Although aberrant mitosis and senescence have been linked, a specific characterization of AURKB in the context of senescence is still required. This proof-of-principle study suggests that our protocol is capable of amplifying tetraploid senescence, which can be observed in only a small population of oncogenic RAS-induced senescence, and provides additional justification for AURKB as a cancer therapeutic target.

1 March 2007 in Experimental Cell Research
Verified
Journal Article
Closed access
NSNedime Serakinci
Nedime Serakinci
RCRikke Christensen
Rikke Christensen
JGJesper Graakjaer
Jesper Graakjaer
CCClaire J. Cairney
Claire J. Cairney
WKW. Nicol Keith
W. Nicol Keith
SKSteen Kolvraa
Steen Kolvraa

11 June 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
RSRaviprakash T. Sitaram
Raviprakash T. Sitaram
CCClaire J. Cairney
Claire J. Cairney
PGPawel Grabowski
Pawel Grabowski
WKW. Nicol Keith
W. Nicol Keith
BHBengt Hallberg
Bengt Hallberg
GRGöran Roos
Göran Roos
DJ‐1 is as a novel regulator of the tumor suppressor PTEN with stimulatory effects on PI3K‐AKT/PKB signaling, one possible target of which is cMyc. The catalytic unit of the telomerase complex, hTERT, can be activated at different levels, including transcriptionally by cMyc and through phosphorylation by AKT/PKB. The aim of the study was to analyze the putative signaling pathway encompassing DJ‐1, cMyc and hTERT in a series of 176 renal cell carcinomas (RCC) and experimentally in cell lines. DJ‐1 mRNA expression was significantly elevated in clear cell RCC (ccRCC) compared with in papillary RCC (pRCC; p = 0.005) and kidney cortex tissue (p < 0.001). ccRCC and pRCC demonstrated higher cMyc RNA levels than in kidney cortex (p < 0.001 for both) as well as increased levels of hTERT RNA (p < 0.001 and p = 0.011, respectively). DJ‐1 was positively correlated to cMyc and hTERT in ccRCC (p < 0.001 and p = 0.019, respectively), but not in pRCC, indicating that this pathway could have a functional significance in ccRCC. siRNA knock down of DJ‐1 induced downregulation of cMyc and hTERT mRNA associated with decreased expression of pAKT and cMyc protein levels. hTERT promoter activity was upregulated after DJ‐1 transfection and this upregulation was inhibited after mutation of the cMyc binding sites. These experimental data support the functional link among DJ‐1, cMyc and hTERT expression as indicated in the tumor material. Neither DJ‐1, cMyc nor hTERT mRNA levels were associated with proliferation (S‐phase fraction), telomere length or prognosis in ccRCC. © 2009 UICC